How to Research a Biotech Stock Without Confusing a Great Story With Great Evidence

Your phone buzzes. A small biotech company you have never heard of has announced “positive topline results,” and its share price is climbing fast. A forum thread calls the drug a game-changer. A friend asks whether you have seen it. What, exactly, should a careful person do with that moment?

This article is about how to research—how to find and read the primary evidence behind a biotech story. It is educational only and is not investment advice. Spin Pharma does not recommend buying, selling or holding any security, and nothing here is a judgement on any company. Biotech shares can move sharply on single events, and decisions about your own money are best made with a licensed financial professional who knows your circumstances.

Two stories that often get confused

Every public biotech company is really two stories running side by side. One is scientific: does the treatment work, for whom, and how safely? The other is financial: what do markets expect, how much cash does the company have, and how will it pay for the next step?

These stories are connected, but they are not the same. A genuinely important scientific result can arrive alongside a falling share price—perhaps because investors expected more, or because the company must now raise money by issuing new shares, which dilutes (shrinks the ownership percentage of) existing shareholders. And a share price can soar on a result that later fails to hold up. Keeping these two stories separate is the single most important habit this guide can offer.

A stock price measures what people expect. A clinical trial measures what actually happened. Learn to read them separately before you read them together.

Step 1: Go to the company’s own filings

Press releases are marketing documents. Regulatory filings are legal ones, and they tend to be more cautious. In the U.S., public companies file with the Securities and Exchange Commission, and those filings are searchable on SEC EDGAR, where you can look up a company by name or its Central Index Key (a unique number the SEC assigns to each filer) and run full-text searches across filings.

The three documents most worth knowing:

• Form 10-K, the annual report. Investor.gov’s guide on how to read a 10-K highlights the Business section, Risk Factors, Management’s Discussion and Analysis, and audited financial statements.
• Form 10-Q, a shorter quarterly update with unaudited financials.
• Form 8-K, a “current report” on significant events. According to Investor.gov’s guide on how to read an 8-K, companies must make most of these disclosures within four business days of the triggering event.

What to look for in a biotech filing

• Pipeline stage: which programs are preclinical (cells and animals), in Phase 1, 2 or 3, or approved?
• Concentration: does the company depend on a single drug or a single trial?
• Cash and “runway”: how long the company itself says its money will last. Treat this as the company’s estimate, not a guarantee.
• Risk Factors: often long and generic, but sometimes the only place a specific manufacturing, licensing or regulatory problem is spelled out.
• Partnerships and licences: who owns which rights, and what payments depend on future milestones.

Step 2: Check the trial, not the headline

Clinical trials are registered on ClinicalTrials.gov, a free, searchable public registry and results database of clinical studies. A registry entry shows the trial’s phase, size, status, and—crucially—its primary outcome measure: the main thing the trial was designed to test, fixed in advance.

A useful exercise is to compare the registered primary outcome with what the press release emphasizes. If the announcement leads with a secondary measure or a subgroup, ask why. Keep one caveat in mind: as the NIH’s page on finding a clinical trial notes, listing a study does not mean it has been evaluated by the U.S. Federal Government. A registry entry is a description, not an endorsement.

Also remember that early promise is fragile. The FDA has documented 22 cases where Phase 2 and Phase 3 results diverged, including cases where the earlier study was relatively large. If you are new to trial design, our explainer Inside a Clinical Trial covers what each phase can and cannot show.

Step 3: Check what the regulator says

Companies describe their own regulatory interactions, but the FDA is the primary source on its decisions. Two places to know:

• Drugs@FDA contains information on FDA-approved drugs, including labels, approval letters and, for many products, the agency’s review documents.
• Complete response letters (CRLs)—the letters the FDA sends when it cannot approve an application in its current form. On July 10, 2025, the FDA announced it had published more than 200 CRLs. In that announcement, the agency cited research finding that sponsors’ public statements about rejections often omitted the FDA’s stated concerns about safety and efficacy.

That last point is the whole article in miniature: the company’s summary and the regulator’s reasoning are different documents, and you learn the most by reading both.

Story signals versus evidence signals

A compelling narrative is not the same as strong data. Some patterns that deserve a second look:

• Big-market framing, small-study data: a release that spends more words on how many people have a disease than on how the trial was designed.
• Preclinical results described in clinical language: words like “cure” or “reverses” applied to mouse or cell studies.
• No comparison group: single-arm results presented as if they had beaten a standard treatment.
• Missing safety details: “well tolerated” without numbers on serious side effects or dropouts.
• Anonymous or paid promotion: enthusiastic content whose authors or funders are unclear.

Our Breakthrough Reality Check offers seven questions that apply to any medical headline, and the Spin Pharma glossary decodes common terms.

A research checklist you can reuse

1. Write down what stage the lead program is actually at: preclinical, Phase 1, 2, 3 or approved.
2. Find the trial on ClinicalTrials.gov and note its registered primary outcome, size and design.
3. Read the latest 10-K’s Business and Risk Factors sections, and any recent 8-Ks.
4. Check whether peer-reviewed data or conference presentations exist beyond the press release.
5. Look for the FDA’s own documents where they exist: labels, reviews or published CRLs.
6. Separately, note the financial facts the company discloses—cash, stated runway, reliance on future fundraising—without letting them colour your reading of the science.
7. Write one sentence summarizing the evidence, and one summarizing the story. Notice where they differ.

This process will not tell you what a share price will do; nothing reliably can. What it offers is clarity about what is known, what is claimed and what is still a hope. For context on how young companies grow in the first place, see our Biotech Startup Map. And once more, because it matters: this is an educational guide, not a recommendation to buy or sell anything.